Cardlytics, Inc. (NASDAQ:CDLX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Cardlytics, Inc. (NASDAQ:CDLX) has been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $12.67.

CDLX has been the topic of a number of analyst reports. Northland Capmk raised Cardlytics to a “strong-buy” rating in a research report on Tuesday, June 18th. Bank of America restated a “neutral” rating and issued a $11.00 price target on shares of Cardlytics in a research report on Thursday, June 20th. Northland Securities initiated coverage on shares of Cardlytics in a research report on Tuesday, June 18th. They set an “outperform” rating and a $14.00 price objective for the company. Craig Hallum decreased their target price on shares of Cardlytics from $18.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $12.00 price objective on shares of Cardlytics in a research note on Tuesday, June 11th.

Insider Activity at Cardlytics

In other Cardlytics news, CEO Karim Saad Temsamani sold 43,129 shares of the business’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $8.65, for a total transaction of $373,065.85. Following the sale, the chief executive officer now owns 385,530 shares of the company’s stock, valued at $3,334,834.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Alexis Desieno sold 7,451 shares of Cardlytics stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $7.95, for a total transaction of $59,235.45. Following the sale, the chief financial officer now directly owns 6,898 shares in the company, valued at approximately $54,839.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Karim Saad Temsamani sold 43,129 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $8.65, for a total transaction of $373,065.85. Following the completion of the transaction, the chief executive officer now owns 385,530 shares of the company’s stock, valued at $3,334,834.50. The disclosure for this sale can be found here. Insiders sold a total of 87,735 shares of company stock valued at $821,738 in the last quarter. Insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Cardlytics

Several hedge funds and other institutional investors have recently bought and sold shares of CDLX. Kent Lake Capital LLC bought a new stake in Cardlytics in the 1st quarter valued at about $3,622,000. Blackstone Inc. acquired a new position in Cardlytics during the 1st quarter valued at about $2,029,000. Perbak Capital Partners LLP acquired a new position in Cardlytics during the 1st quarter valued at about $2,348,000. Price T Rowe Associates Inc. MD increased its holdings in Cardlytics by 6.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock worth $432,000 after purchasing an additional 1,774 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in shares of Cardlytics in the first quarter worth approximately $1,906,000. Institutional investors and hedge funds own 68.10% of the company’s stock.

Cardlytics Stock Up 0.4 %

Shares of CDLX stock opened at $8.45 on Friday. The firm’s fifty day moving average price is $8.66 and its two-hundred day moving average price is $9.49. Cardlytics has a 1 year low of $5.71 and a 1 year high of $20.52. The company has a current ratio of 2.13, a quick ratio of 2.13 and a debt-to-equity ratio of 1.30. The firm has a market capitalization of $412.19 million, a P/E ratio of -1.91 and a beta of 1.65.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.35) EPS for the quarter. The company had revenue of $67.61 million during the quarter. Cardlytics had a negative net margin of 55.23% and a negative return on equity of 25.36%. On average, equities analysts predict that Cardlytics will post -1.8 EPS for the current fiscal year.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.